ridaforolimus also known formerly known investigational targeted smallmolecule inhibitor protein mtor protein acts central regulator protein synthesis cell proliferation cell cycle progression cell survival integrating signals proteins akt pten known important malignancy blocking mtor creates starvationlike effect cancer cells interfering cell growth division metabolism promising results clinical trial advanced soft tissue bone sarcoma ridaforolimus codeveloped merck ariad pharmaceuticals may ariad pharmaceuticals merck company announced clinical development marketing agreement agreement ariad received million upfront payments merck million milestone payments future payments triggered upon acceptance nda fda another payment drug receives marketing approval similar milestones acceptance approval europe japan milestone payments tied revenue goals ariad opted copromote ridaforolimus us merck plans submit new drug application nda ridaforolimus us food drug administration fda marketing application european union formal rejection fda june ariadmsd decided withdraw ema application ridaforolimus november june ariad merck announced detailed results largest randomized study ever soft tissue bone sarcoma population phase iii succeed clinical trial succeed evaluated oral ridaforolimus patients metastatic softtissue bone sarcomas previously favorable response chemotherapy patient population ridaforolimus improved progressionfree survival pfs compared placebo primary endpoint study complete study results presented sant p chawla md director sarcoma oncology center santa monica ca american society clinical oncology asco annual meeting succeed sarcoma multicenter clinical evaluation efficacy ridaforolimus trial randomized placebocontrolled doubleblind study oral ridaforolimus administered mgday five seven days per week patients metastatic softtissue bone sarcomas previously favorable response chemotherapy oral ridaforolimus granted special protocol assessment spa fda succeed trial based progressionfree survival pfs events patients ridaforolimus placebo determined independent radiological review committee study achieved primary endpoint improvement pfs statistically significant percent reduction risk progression death observed treated ridaforolimus compared placebo hazard median pfs weeks treated ridaforolimus compared weeks placebo group furthermore based full analysis pfs determined investigator assessment statistically significant percent reduction ridaforolimus risk progression death compared placebo hazard investigator assessment analysis median pfs weeks treated ridaforolimus compared weeks placebo group httpsenwikipediaorgwikiridaforolimus